Jim M. Koeller, MS

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.

Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.